论文部分内容阅读
目的:探讨紫杉醇(TAX)单药全身化疗联合顺铂(DDP)+5-氟尿嘧啶(5-FU)腹腔化疗治疗胃癌并发腹腔积液的疗效和不良反应。方法:选择胃癌并发腹腔积液患者32例。全身化疗2个周期后评价腹腔积液疗效和患者近期的不良反应。结果:32例患者均可评价疗效,总有效率为75%,其中,完全缓解(CR)11例(34.4%),部分缓解(PR)13例(40.6%),稳定(SD)6例(0.2%),进展(PD)2例(6.25%),总有效率(CR+PR)占75%。结论:单药TAX全身化疗联合DDP+5-FU腹腔化疗治疗胃癌并发腹腔积液,疗效可靠,患者耐受性好。
OBJECTIVE: To investigate the efficacy and adverse reactions of paclitaxel (TAX) single-agent systemic chemotherapy combined with cisplatin (DDP) plus 5-fluorouracil (5-FU) intraperitoneal chemotherapy for gastric cancer complicated with peritoneal effusion. Methods: Twenty-two patients with gastric cancer complicated with peritoneal effusion were selected. After 2 cycles of systemic chemotherapy, the efficacy of peritoneal effusion and the patient’s recent adverse reactions were evaluated. RESULTS: All 32 patients could evaluate the curative effect. The total effective rate was 75%. Among them, 11 cases (34.4%) were complete remission (CR), 13 cases (40.6%) were partial remission (PR), and 6 cases were stable (SD). 0.2%), progress (PD) 2 cases (6.25%), and total effective rate (CR+PR) accounted for 75%. CONCLUSION: The single-agent TAX systemic chemotherapy combined with DDP+5-FU intraperitoneal chemotherapy for the treatment of gastric cancer complicated by peritoneal effusion is reliable and well tolerated.